<DOC>
	<DOCNO>NCT02389751</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose ganetespib give combination standard chemotherapy ( paclitaxel carboplatin ) radiation therapy patient esophageal cancer .</brief_summary>
	<brief_title>A Study Ganetespib Combination With Chemoradiation</brief_title>
	<detailed_description>Study Groups : If participant find eligible take part study , assign dose level ganetespib base join study . Up 3 dose level ganetespib test . The first group participant receive low dose level . Each new group receive high dose level group , intolerable side effect see . This continue high tolerable dose ganetespib find . All participant receive standard dose level paclitaxel carboplatin . Study Treatment : Participant also receive radiation therapy 5 day week ( Monday-Friday ) 5 ½ week . Each radiation treatment take minute , appointment last 1 hour . On first day radiation ( Monday , Tuesday , Wednesday ) every week radiation , participant receive ganetespib . Participant also give paclitaxel vein 1 hour carboplatin vein 30 minute . Study Tests : Each week treatment Weeks 1 , 2 , 3 : - Participant physical exam . - Blood ( 2 teaspoon ) draw routine test . - Participant EKG right ganetespib infusion 24hours ganetespib infusion . Each week treatment Weeks 4 5 : - Participant physical exam . - Blood ( 2 teaspoon ) draw routine test . - Participant EKG right ganetespib infusion . Participant another EKG 24 hour infusion previous abnormal EKG result . Participant 's dose ganetespib may adjust stop time base EKG result . About 6 week treatment , participant follow test procedure help doctor decide standard care surgery : - Participant physical exam . - Blood ( 2 teaspoon ) draw routine test . - Participant FDG-PET/CT scan and/or CT scan check status disease . - Participant endoscopic biopsy check status disease . Surgery : If participant 's doctor decide surgery , surgery perform MD Anderson 8 10 week finish chemotherapy radiation therapy . If participant need surgery , give separate consent form describe surgery risk . At time surgery , participant physical exam part routine care . Length Treatment : Participant receive treatment 6 week . Participant longer able receive treatment disease get bad , intolerable side effect occur , unable follow study direction . Patient 's participation study follow-up visit . Follow-up Testing : If disease come back participant study , follow test perform : - Participant physical exam . - Participant endoscopic biopsy check status disease . - If already do , participant CT scan FDG-PET/CT scan check status disease . Participant ask return clinic follow-up test . Participants follow-up visit every 3 month 1 year , unless take study . After 1 year , participant follow-up visit every 4 month second year radiation therapy , every 6 month next 3 year . At follow-up visit , follow test perform : - Participant physical exam . - Blood ( 2 teaspoon ) draw routine test . - Participant PET/CT and/or CT scan check status disease . - If participant 's doctor think best interest , endoscopic biopsy check status disease . - Participant also receive nutritional assessment counseling , need . This investigational study . Ganetespib FDA approve commercially available . It currently use research purpose . Paclitaxel , carboplatin , radiation therapy FDA approve consider standard treatment esophageal cancer . The combination paclitaxel , carboplatin , ganetespib , radiation therapy investigational . The study doctor explain study drug design work . Up 40 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histologically documented adenocarcinoma squamous cell carcinoma cervical esophagus , thoracic esophagus , gastroesophageal junction 2 . Stage II III esophageal carcinoma accord AJCC 7th edition stag 3 . EGD EUS +/ biopsy M.D . Anderson require confirm stag 4 . ECOG performance status &lt; /= 1 ( Karnofsky &gt; /= 70 % ) 5 . Patients contraindication chemotherapy radiation , receive either definitive chemoradiation therapy preoperative chemoradiation therapy 6 . Age &gt; /= 18 year , currently dose adverse event data available use Ganetespib patient &lt; 18 year age 7 . Patients must receive baseline FDGPET/CT +/ CT contrast within 1 month +/ 2 week prior study entry , contraindication PET CT image 8 . There adequate wellcontrolled study pregnant woman use Ganetespib . For reason radiation know teratogenic , woman childbearing potential men must agree adequate contraception ( hormonal barrier method birth control ; abstinence ) 30 day discontinue treatment 9 . Women childbearing potential must negative serum pregnancy test within 14 day study entry . Should woman become pregnant suspect pregnant partner participate study , inform treat physician immediately 10 . Patients must adequate organ marrow function define : *Absolute neutrophil count ( ANC ) &gt; /= 1.5x109/L ; *WBC &gt; /= 2500 cells/µl ; *Hemoglobin &gt; /= 9 g/dL ; *Platelets &gt; /= 100x109/L ; *Albumin &gt; /= 2.5 g/dL ; *Serum bilirubin &lt; /= 1.5x institutional upper limit normal ( ULN ) ; *Total bilirubin &lt; /= 1.5x institutional ULN ; *Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; /= 2.5x institutional ULN ; *Serum creatinine &lt; /= 1.5 mg/dL OR calculate creatinine clearance ( CockcroftGault formula ) &gt; /= 50 mL/min OR 24hour urine creatinine clearance &gt; /= 50 mL/min ; *Prothrombin time ( PT ) /International normalize ratio ( INR ) partial thromboplastin time ( PTT ) &lt; /= 1.5x institutional ULN 11 . Baseline screen QTc &lt; 470 m eligible . 1 . Prior radiation chest abdomen 2 . Previous concomitant malignancy EXCEPTIONS : Patients curatively treat carcinoma situ cervix , basal cell skin , transitional cell carcinoma bladder , early stage cancer nonoverlapping site evidence disease &gt; /= 3 year . 3 . No induction chemotherapy 4 . Pregnant breastfeeding female . Patients become pregnant active therapy immediately remove study . 5 . Uncontrolled intercurrent illness serious medical condition include , limited : *Clinically significant , uncontrolled , major cardiac , respiratory , renal , hepatic , gastrointestinal , hematologic disease ; *Active uncontrolled infection ; *Symptomatic congestive heart failure , unstable angina , cardiac dysrrhythmia control pacer device ; *No myocardial infarction within 3 month registration ; *Symptomatic inflammatory bowel disease uncontrolled diarrhea 6 . Major cardiacrelated disease , medication , laboratory abnormality include follow : ) Clinically unstable cardiac disease , include unstable atrial fibrillation , symptomatic bradycardia , unstable congestive heart failure , active myocardial ischemia , indwell temporary pacemaker , b ) Ventricular tachycardia supraventricular tachycardia require treatment Class Ia antiarrhythmic drug ( eg , quinidine , procainamide , disopyramide ) Class III antiarrhythmic drug ( eg , sotalol , amiodarone , dofetilide ) . Use antiarrhythmic drug permit . c ) Use medication link occurrence torsades de pointes , ) Second thirddegree atrioventricular ( AV ) block unless treat permanent pacemaker , e ) Complete leave bundle branch block ( LBBB ) , f ) History long QT Syndrome family member condition , 7 . Exclusion # 6 continue : g ) If baseline QTc &gt; 470 m , average triplicate ECG recording necessary . If average value QTc &gt; 470ms , patient ineligible study . h ) Serum potassium , magnesium , calcium level outside laboratory 's reference range . 8 . Known immediate delay hypersensitivity reaction carboplatin , paclitaxel , polysorbate 80 , component formulation 9 . Any major surgery , extensive radiotherapy , chemotherapy delay toxicity , biologic therapy , immunotherapy within 21 day prior study registration , and/or daily weekly chemotherapy without potential delayed toxicity within 14 day prior registration 10 . Use investigational drug within 28 day ( five halflives , whichever short ; minimum 14 day last dose ) either precede first dose Ganetespib study period 11 . Current use prohibit medication . The following medication nondrug therapy prohibit : ) Other anticancer therapy study treatment , b ) Because composition , PK , metabolism many herbal supplement unknown , concurrent use herbal supplement prohibit study ( include , limited , St. John 's wort , kava , ephedra [ huang ] , gingko biloba , dehydroepiandrosterone [ DHEA ] , yohimbe , saw palmetto , ginseng ) 12 . Known Human Immunodeficiency Virus ( HIV ) , active Hepatitis B Virus ( HBV ) , active Hepatitis C virus ( HCV ) infection ( exception chronic clear HBC HCV infection , allow ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Esophageal carcinoma</keyword>
	<keyword>Adenocarcinoma squamous cell carcinoma gastroesophageal junction</keyword>
	<keyword>Adenocarcinoma squamous cell carcinoma cervical esophagus</keyword>
	<keyword>Adenocarcinoma squamous cell carcinoma thoracic esophagus</keyword>
	<keyword>Ganetespib</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
</DOC>